Cerebrotendinous xanthomatosis and pregnancy: A multicenter study of maternal and neonatal outcomes with a focus on chenodeoxycholic acid treatment during gestation

dc.contributor.authorZubarioglu, Tanyel
dc.contributor.authorYalcin-Cakmakli, Gul
dc.contributor.authorYildiz, Yilmaz
dc.contributor.authorBulut, Fatma Derya
dc.contributor.authorKor, Deniz
dc.contributor.authorYildiz, Sevil
dc.contributor.authorAktuglu-Zeybek, Cigdem
dc.date.accessioned2026-09-08T07:13:33Z
dc.date.issued2026
dc.departmentFırat Üniveristesi
dc.description.abstractBACKGROUND: Cerebrotendinous xanthomatosis (CTX) is a progressive neurometabolic disorder, and chenodeoxycholic acid (CDCA) is the primary treatment that effectively prevents disease progression. However, using CDCA during pregnancy presents clinical challenges due to limited safety data and theoretical concerns about fetal teratogenicity. OBJECTIVE: This study aims to evaluate maternal and neonatal outcomes in genetically confirmed CTX pregnancies and to assess the safety profile of CDCA when used during pregnancy. METHODS: This retrospective, multicenter study included 19 pregnancies in 12 women with CTX. Data were collected on maternal neurological status, pregnancy outcomes, neonatal characteristics, and long-term offspring development. CDCA treatment status during pregnancy was documented, and outcomes were compared. RESULTS: Of the 19 pregnancies, 16 resulted in live births (84.2%), whereas 3 ended in spontaneous abortions-all in a single undiagnosed patient. Among the 5 pregnancies with a prior CTX diagnosis, 4 were treated with CDCA during gestation. No maternal neurological deterioration or fetal malformations were observed in CDCA-treated pregnancies. In contrast, adverse findings, including neurological decline in 1 mother, a case of spina bifida, and cognitive impairment in offspring, were limited to pregnancies without CDCA treatment. No fetal or neonatal complications suggestive of CDCA-related toxicity were detected. CONCLUSION: Our findings support evidence that continuing CDCA therapy during pregnancy in women with CTX is associated with favorable maternal and fetal outcomes, with no clear indications of teratogenicity. Maintaining CDCA treatment appears to contribute to maternal neurological stability. (c) 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
dc.identifier.doi10.1016/j.jacl.2026.04.004
dc.identifier.endpage1195
dc.identifier.issn1933-2874
dc.identifier.issn1876-4789
dc.identifier.issue6
dc.identifier.orcid0000-0002-5521-7659
dc.identifier.orcid0000-0001-6947-2573
dc.identifier.pmid42067461
dc.identifier.scopus2-s2.0-105037323574
dc.identifier.scopusqualityQ1
dc.identifier.startpage1186
dc.identifier.urihttps://doi.org/10.1016/j.jacl.2026.04.004
dc.identifier.urihttps://hdl.handle.net/11508/65497
dc.identifier.volume20
dc.identifier.wosWOS:001794258900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Clinical Lipidology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250903
dc.subjectXanthomatosis
dc.subjectCerebrotendinous
dc.subjectChenodeoxycholic Acid
dc.subjectPregnancy
dc.titleCerebrotendinous xanthomatosis and pregnancy: A multicenter study of maternal and neonatal outcomes with a focus on chenodeoxycholic acid treatment during gestation
dc.typeArticle

Dosyalar